<p>MSCI has reported quite a good fourth quarter and full year, marking a recovery in most operating statistics, such as run rates and retention rates, signalling a favourable environment. The integration of RiskMetrics appears to be going smoothly and it looks like MSCI has decided to keep RiskMetrics' Governance segment for good, despite its being quite different from the rest of the business.</p>

<p>Most segments posted good growth on a pro forma basis, with the exception of the governance and portfolio management analytics segments, on which the company says it will focus specifically. MSCI revealed that a separate sales force is being deployed for governance products, while a new product launch - the Barra Portfolio Manager - is supposed to address the company's weaknesses in the portfolio analytics segment. MSCI has stated that the company is ready to ramp up investments now that the integration of RiskMetrics is progressing well, suggesting that the company may start looking for new acquisition targets and may boost its internal R&amp;D efforts.</p>

<p>Overall, the prospects for the company remain good. We did not change our model assumptions and simply reflected updated financials and peer valuations. As such, our valuation remains largely the same, suggesting that at $34.58 MSCI's stock represents fair value. That is only slightly below the current market price (4%) and thus we remain neutral on this stock.</p>

<p>&nbsp;</p>

  • LinkedIn  
  • Save this article
  • Print this page  

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@chartis-research.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Chartis Research? View our subscription options

You need to sign in to use this feature. If you don’t have a Chartis account, please register for an account.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here.